注射用血栓通辅助治疗急性脑梗死临床研究  

Clinical Study on Xueshuantong(血栓通) for Injectionas An Adjuvant Therapy for Acute Cerebral Infarction

作　　者：汪建平[1] WANG Jianping(The Second Department of Internal Medicine,The Third Affiliated Hospital of Luohe Medical College,Luohe 462000,Henan,China)

机构地区：[1]漯河医学高等专科学校第三附属医院内二科,河南漯河462000

出　　处：《辽宁中医杂志》2024年第3期107-111,共5页Liaoning Journal of Traditional Chinese Medicine

摘　　要：目的探讨急性脑梗死患者经注射用血栓通治疗后其脑血流动力学、炎症指标及神经细胞因子的变化情况。方法根据随机数字表法分配原则将152例2020年1月—2022年8月该院收治的急性脑梗死患者分为对照组(76例)和试验组(76例)。两组均给予常规治疗,对照组在常规治疗基础上给予依达拉奉注射液进行治疗,试验组在对照组基础上给予注射用血栓通进行治疗,两组均连续治疗2周。比较两组治疗2周后的疗效,治疗前和治疗2周后的临床相关评分、脑血流动力学、炎症指标、神经细胞因子及治疗期间的安全性。结果与对照组比较,试验组治疗2周后的总有效率较高[93.42%(71/76)vs 81.58%(62/76),P<0.05)]。治疗2周后,两组美国国立卫生院卒中量表(National Institutes of Health stroke scale,NIHSS)、改良Rankin量表(improved Rankin scale,mRS)评分、动态阻力(dynamic resistance,DR)、外周阻力(peripheral resistance,Rv)及血清基质金属蛋白酶-9(matrix metalloproteinases-9,MMP-9)、同型半胱氨酸(homocysteine,Hcy)、C反应蛋白(C-reactive protein,CRP)、白细胞介素-2(interleukin-2,IL-2)、肿瘤坏死因子-α(tumor necrosis factor-α,TNF-α)、神经元特异性烯醇化酶(neuron specific enolase,NSE)水平与治疗前比较均降低,试验组低于对照组(P<0.05);两组Barthel指数(Barthel index,BI)评分、平均血流速度(mean blood flow velocity,Vm)、平均血流量(mean blood flow,Qm)及血清神经营养因子(neurotrophic factor,NTF)、神经生长因子(nerve growth factor,NGF)、胰岛素样生长因子-1(insulin-like growth factor-1,IGF-1)水平与治疗前比较均升高,试验组高于对照组(P<0.05)。治疗期间,试验组不良反应总发生率为6.58%(5/76),与对照组(9.21%,7/76)比较,差异无统计学意义(P>0.05)。结论注射用血栓通可有效调节急性脑梗死患者炎症指标及神经细胞因子,减轻机体炎症及神经功能缺损程度,改善神经功能,并可平衡脑血流�Objective To investigate thechanges of cerebral hemodynamics,inflammatory indicators and neurocytokines in patients with acute cerebral infarction after treatment with Xueshuantong(血栓通)for Injection.Methods A total of 152 patients with acute cerebral infarction admitted to the hospital from January 2020 to August 2022 were divided into the control group(76 cases)and the test group(76 cases)according to the distribution principle of random number table.Both groups were given the routine treatment.The control group was given Edaravone Injection on the basis of routine treatment,and the test group was given Xueshuantongfor Injection on the basis of the control group.Both groups were treated continuously for 2 weeks.The efficacy after 2 weeks of treatment,the scores of clinical related,cerebral hemodynamics,inflammatory indicators,neurocytokines before and after 2 weeks of treatmentand safety during treatment of the two groups were compared.Results Compared with that of the control group,the total effective rate of the test group after 2 weeks of treatment was higher[93.42%(71/76)vs 81.58%(62/76),P<0.05)].After 2 weeks of treatment,the scores of National Institutes of Health stroke scale(NIHSS),modified Rankin scale(mRS),dynamic resistance(DR),peripheral resistance(Rv),and serum levels of matrix metalloproteinase-9(MMP-9),homocysteine(Hcy),C-reactive protein(CRP),interleukin-2(IL-2),tumor necrosis factor-α(TNF-α)and neuron specific enolase(NSE)in the two groups were lower than those before treatment,and those in the test group were lower than those in the control group(P<0.05).The score of Barthel index(BI),mean blood flow velocity(Vm),mean blood flow(Qm)and serum levels of neurotrophic factor(NTF),nerve growth factor(NGF)and insulin-like growth factor-1(IGF-1)in the two groups were higher than those before treatment,and those in the test group were higher than those in the control group(P<0.05).The total incidence of adverse reactions during treatmentin the test group was 6.58%(5/76),and there was no signifi

关 键 词：急性脑梗死 注射用血栓通 依达拉奉注射液 脑血流动力学 炎症 神经细胞因子 安全性 

分 类 号：R25[医药卫生—中医内科学]